BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.

Key facts

Sponsor

Hospices Civils de Lyon

Intervention

Histopathological analysis(other)

Enrollment

135 enrolled

Eligibility

25-100 years · All sexes

Timeline

2024 – 2025

Study locations (1)

• Hopital Lyon Sud - HCL, Pierre-Bénite, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for MALT lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06510309
  Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
  Gottfried von Keudell, MD PhD
• RECRUITINGPHASE2NCT07441993
  Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE2NCT07372365
  Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE2NCT06796998
  Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
  Izidore Lossos, MD
• RECRUITINGNCT06712459
  Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
  International Extranodal Lymphoma Study Group (IELSG)
• ACTIVE NOT RECRUITINGPHASE2NCT07480863
  Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• ACTIVE NOT RECRUITINGPHASE2NCT07247383
  Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
  Second Affiliated Hospital, School of Medicine, Zhejiang University
• RECRUITINGPHASE2NCT07208981
  Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
  The First Affiliated Hospital with Nanjing Medical University

See all trials for MALT lymphoma →